Edgewise Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
EWTX$48.74+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · As of · · As of | ||||||
| · · March 31, · · December 31, | ||||||
| · 2025 · 2024 | ||||||
| Assets · · (unaudited) · · | ||||||
| Current assets · · · | ||||||
| Cash and cash equivalents | | $49,921 | $41,666 | |||
| Marketable securities, available for sale | | 386,466 | | 428,504 | ||
| Prepaid expenses and other assets | | 6,791 | | 5,313 | ||
| Total current assets | | 443,178 | | 475,483 | ||
| | | | | | | |
| Property and equipment, net | | 8,990 | | 9,503 | ||
| Operating lease right-of-use asset | | | 1,528 | | | 1,569 |
| Other non-current assets | | 695 | | 262 | ||
| | | | | | | |
| Total assets | | $454,391 | | $486,817 | ||
| | | | | | | |
| Liabilities and stockholders' equity | | | ||||
| | | | | | | |
| Current liabilities | | | | |||
| Accounts payable | | $8,789 | | $5,579 | ||
| Accrued compensation | | 3,974 | | 10,056 | ||
| Accrued other expenses | | 7,351 | | 7,229 | ||
| Operating lease liability, current portion | | | 1,001 | | | 996 |
| Total current liabilities | | 21,115 | | 23,860 | ||
| Operating lease liability, net of current portion | | | 3,557 | | | 3,741 |
| | | | | | | |
| Total liabilities | | 24,672 | | 27,601 | ||
| | | | | | | |
| Commitments and contingencies (see note 5) | | | | |||
| | | | | | | |
| Stockholders' equity: | | | ||||
| Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2025 and December 31, 2024 | | | — | | | — |
| Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 95,205,683 shares and 94,838,466 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | | 9 | | 9 | ||
| Additional paid-in capital | | 848,683 | | 837,363 | ||
| Accumulated other comprehensive income | | | 401 | | | 420 |
| Accumulated deficit | | (419,374) | | (378,576) | ||
| Total stockholders' equity | | 429,719 | | 459,216 | ||
| | | | | | | |
| Total liabilities and stockholders' equity | | $454,391 | | $486,817 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.